Neither Haloperidol nor Quetiapine Should Be Used for Insomnia
Both haloperidol (Haldol) and quetiapine (Seroquel) are strongly advised against for the treatment of insomnia, with quetiapine carrying particularly serious risks in older adults including increased mortality, dementia, and falls. 1, 2
Why These Medications Should Be Avoided
Quetiapine (Seroquel) - Strong Evidence Against Use
The 2019 VA/DoD guidelines explicitly advise against using antipsychotics for chronic insomnia disorder 1. The evidence is clear:
Sparse and inconclusive efficacy data: Only one small RCT (n=13) showed no statistically significant improvement in total sleep time, sleep latency, or sleep satisfaction compared to placebo, despite trends toward improvement 3
Serious safety concerns in older adults: A 2025 study found quetiapine associated with:
- 3.1-fold increased mortality risk vs. trazodone (HR 3.1,95% CI 1.2-8.1)
- 8.1-fold increased dementia risk vs. trazodone (HR 8.1,95% CI 4.1-15.8)
- 2.8-fold increased fall risk vs. trazodone (HR 2.8,95% CI 1.4-5.3) 2
Known harms at all doses: Increased risk of death in elderly patients with dementia-related psychosis, increased suicidal tendencies in young adults, metabolic effects, and weight gain 1
FDA approval: Quetiapine is approved only for schizophrenia and bipolar disorder—not insomnia 4
Haloperidol (Haldol) - No Evidence for Insomnia
Haloperidol has no established role in insomnia treatment and carries the same class warnings as other antipsychotics regarding increased mortality in elderly patients with dementia 1. It was only included as a comparator in schizophrenia trials, not studied for sleep 4.
What Should Be Used Instead
First-line treatment: Cognitive-behavioral therapy for insomnia (CBT-I), either in-person or digitally 5
If pharmacotherapy is needed (when CBT-I is insufficient):
- Short-term (≤4 weeks): Benzodiazepine receptor agonists (e.g., zolpidem, eszopiclone), daridorexant, or low-dose sedating antidepressants 6, 5
- Longer-term: Orexin receptor antagonists (up to 3 months or longer) 5
- Patients ≥55 years: Prolonged-release melatonin (up to 3 months) 5
Critical Pitfalls to Avoid
The widespread off-label use of quetiapine for insomnia (likely to avoid controlled substances) is not supported by evidence and exposes patients to serious harm 7, 8, 9. The 2023 European Insomnia Guideline explicitly states that antipsychotics are not recommended for insomnia treatment 5. Even the most recent meta-analysis (2023) showing some sleep quality improvement with quetiapine noted high rates of adverse events and discontinuation 10, and this benefit does not outweigh the mortality and dementia risks demonstrated in the 2025 safety study 2.
The answer is clear: use neither medication for insomnia. Start with CBT-I, and if pharmacotherapy is required, use FDA-approved insomnia medications with established safety profiles.
budget:token_budget Tokens used this turn: 3851 Tokens remaining: 196149